SLC5A2 and type 2 diabetes mellitus: Since the introduction of glucagon-like peptide-1 receptor agonists (GLP-1RA) in 2005 and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in 2012, these has been a recent shift in the treatment paradigm for T2D (3, 4).